aTyr Pharma, Inc. (NasdaqCM: ATYR)
Health Care · Biotechnology · US
$0.57
+7.55% today · -89.0% 1Y
aTyr Pharma, Inc. (NasdaqCM: ATYR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $55.91M and employs 58 people.
Over the last twelve months the share price has lost 89.0%, trading between 0.40 and 6.50.
Tweenvest scores aTyr Pharma, Inc. across four factors: quality 26/100, value 35/100. Its strongest factor is value.
ATYR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $55.91M
- Revenue (TTM)
- $190.00K
- P/E
- —
- EPS
- -0.62
- Dividend yield
- —
- Beta (5Y)
- 0.52
- 52-week high
- $6.50
- 52-week low
- $0.40
- Avg volume (3M)
- —
- Shares outstanding
- 98.09M
- Employees
- 58
- Next earnings
- —
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
- ISIN
- US0021202025
- Founded
- 2005
- Listed since
- May 7, 2015
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.